Common use of SUPPLEMENTAL INDENTURES 29 Clause in Contracts

SUPPLEMENTAL INDENTURES 29. Section 9.01 Supplemental Indentures Without the Consent of Securityholders 29 Section 9.02 Supplemental Indentures With Consent of Securityholders 30 Section 9.03 Effect of Supplemental Indentures 30 Section 9.04 Securities Affected by Supplemental Indentures 30 Section 9.05 Execution of Supplemental Indentures 30 ARTICLE 10 SUCCESSOR ENTITY 31 Section 10.01 Company May Consolidate, Etc. 31 Section 10.02 Successor Entity Substituted 31 ARTICLE 11 SATISFACTION AND DISCHARGE 31 Section 11.01 Satisfaction and Discharge of Indenture 31 Section 11.02 Discharge of Obligations 32 Section 11.03 Deposited Moneys to be Held in Trust 32 Section 11.04 Payment of Moneys Held by Paying Agents 32 Section 11.05 Repayment to Company 32 ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 33 Section 12.01 No Recourse 33 ARTICLE 13 MISCELLANEOUS PROVISIONS 33 Section 13.01 Effect on Successors and Assigns 33 Section 13.02 Actions by Successor 33 Section 13.03 Surrender of Company Powers 33 iii. Table Of Contents (continued) Page Section 13.04 Notices 33 Section 13.05 Governing Law; Jury Trial Waiver 34 Section 13.06 Treatment of Securities as Debt 34 Section 13.07 Certificates and Opinions as to Conditions Precedent 34 Section 13.08 Payments on Business Days 34 Section 13.09 Conflict with Trust Indenture Act 35 Section 13.10 Counterparts 35 Section 13.11 Separability 35 Section 13.12 Compliance Certificates 35 Section 13.13 Patriot Act 35 Section 13.14 Force Majeure 35 Section 13.12 Table of Contents; Headings 35 iv. INDENTURE Indenture, dated as of , 20 , among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):

SUPPLEMENTAL INDENTURES 29. Section 9.01 9.1 Supplemental Indentures Without the Consent of Securityholders 29 Section 9.02 9.2 Supplemental Indentures With Consent of Securityholders 30 Section 9.03 9.3 Effect of Supplemental Indentures 30 Section 9.04 9.4 Securities Affected by Supplemental Indentures 30 Section 9.05 9.5 Execution of Supplemental Indentures 30 ARTICLE 10 X SUCCESSOR ENTITY 31 Section 10.01 10.1 Company May Consolidate, Etc. Etc 31 Section 10.02 10.2 Successor Entity Substituted 31 Section 10.3 Evidence of Consolidation, Etc 31 ARTICLE 11 XI SATISFACTION AND DISCHARGE 31 32 Section 11.01 11.1 Satisfaction and Discharge of Indenture 31 32 Section 11.02 11.2 Discharge of Obligations 32 Section 11.03 11.3 Deposited Moneys to be Held in Trust 32 Section 11.04 11.4 Payment of Moneys Held by Paying Agents 32 Section 11.05 11.5 Repayment to Company 32 ARTICLE 12 XII IMMUNITY OF INCORPORATORS, STOCKHOLDERSSHAREHOLDERS, OFFICERS AND DIRECTORS 33 Section 12.01 12.1 No Recourse 33 ARTICLE 13 XIII MISCELLANEOUS PROVISIONS 33 Section 13.01 13.1 Effect on Successors and Assigns 33 Section 13.02 13.2 Actions by Successor 33 Section 13.03 13.3 Surrender of Company Powers 33 iii. Table Of Contents (continued) Page Section 13.04 13.4 Notices 33 Section 13.05 13.5 Governing Law; Jury Trial Waiver Law 34 Section 13.06 13.6 Treatment of Securities as Debt 34 Section 13.07 13.7 Certificates and Opinions as to Conditions Precedent 34 Section 13.08 13.8 Payments on Business Days 34 Section 13.09 13.9 Conflict with Trust Indenture Act 35 34 Section 13.10 Counterparts 35 34 Section 13.11 Separability 35 Section 13.12 Compliance Certificates 35 Section 13.13 Patriot Act 35 Section 13.14 Force Majeure 35 Section 13.12 Table of Contents; Headings 35 iv. INDENTURE Indenture, dated as of , 20 , among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):35

SUPPLEMENTAL INDENTURES 29. Section 9.01 9.1 Supplemental Indentures Without the Consent of Securityholders 29 Section 9.02 9.2 Supplemental Indentures With Consent of Securityholders 30 Section 9.03 9.3 Effect of Supplemental Indentures 30 Section 9.04 9.4 Securities Affected by Supplemental Indentures 30 Section 9.05 9.5 Execution of Supplemental Indentures 30 31 ARTICLE 10 X SUCCESSOR ENTITY 31 Section 10.01 10.1 Company May Consolidate, Etc. Etc 31 Section 10.02 10.2 Successor Entity Substituted 31 32 Section 10.3 Evidence of Consolidation, Etc 32 ARTICLE 11 XI SATISFACTION AND DISCHARGE 31 32 Section 11.01 11.1 Satisfaction and Discharge of Indenture 31 32 Section 11.02 11.2 Discharge of Obligations 32 Section 11.03 11.3 Deposited Moneys to be Held in Trust 32 33 Section 11.04 11.4 Payment of Moneys Held by Paying Agents 32 33 Section 11.05 11.5 Repayment to Company 32 33 ARTICLE 12 XII IMMUNITY OF INCORPORATORS, STOCKHOLDERSSHAREHOLDERS, OFFICERS AND DIRECTORS 33 Section 12.01 12.1 No Recourse 33 ARTICLE 13 XIII MISCELLANEOUS PROVISIONS 33 34 Section 13.01 13.1 Effect on Successors and Assigns 33 34 Section 13.02 13.2 Actions by Successor 33 34 Section 13.03 13.3 Surrender of Company Powers 33 iii. Table Of Contents (continued) Page Section 13.04 Notices 33 Section 13.05 Governing Law; Jury Trial Waiver 34 Section 13.06 13.4 Notices 34 Section 13.5 Governing Law 34 Section 13.6 Treatment of Securities as Debt 34 Section 13.07 13.7 Certificates and Opinions as to Conditions Precedent 34 Section 13.08 13.8 Payments on Business Days 34 35 Section 13.09 13.9 Conflict with Trust Indenture Act 35 Section 13.10 Counterparts 35 Section 13.11 Separability 35 Section 13.12 Compliance Certificates 35 Section 13.13 Patriot Act 35 Section 13.14 Force Majeure 35 Section 13.12 Table of Contents; Headings 35 iv. INDENTURE Indenture, dated as of , 20 , among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):35

SUPPLEMENTAL INDENTURES 29. Section 9.01 Supplemental Indentures Without the Consent of Securityholders Securityholders. 29 Section 9.02 Supplemental Indentures With Consent of Securityholders Securityholders. 30 Section 9.03 Effect of Supplemental Indentures 30 Indentures. 31 Section 9.04 Securities Affected by Supplemental Indentures 30 Indentures. 31 Section 9.05 Execution of Supplemental Indentures 30 Indentures. 31 ARTICLE 10 SUCCESSOR ENTITY 31 Section 10.01 Company May Consolidate, Etc. 31 Section 10.02 Successor Entity Substituted 31 Substituted. 32 ARTICLE 11 SATISFACTION AND DISCHARGE 31 32 Section 11.01 Satisfaction and Discharge of Indenture 31 Indenture. 32 Section 11.02 Discharge of Obligations 32 Obligations. 33 Section 11.03 Deposited Moneys to be Held in Trust 32 Trust. 33 Section 11.04 Payment of Moneys Held by Paying Agents 32 Agents. 33 Section 11.05 Repayment to Company 32 Company. 33 ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 33 Section 12.01 No Recourse Recourse. 33 ARTICLE 13 MISCELLANEOUS PROVISIONS 33 34 Section 13.01 Effect on Successors and Assigns 33 Assigns. 34 Section 13.02 Actions by Successor 33 Successor. 34 Section 13.03 Surrender of Company Powers 33 iiiPowers. Table Of Contents (continued) Page 34 Section 13.04 Notices 33 Notices. 34 Section 13.05 Governing Law; Jury Trial Waiver Waiver. 34 Section 13.06 Treatment of Securities as Debt Debt. 34 Section 13.07 Certificates and Opinions as to Conditions Precedent 34 Precedent. 35 Section 13.08 Payments on Business Days 34 Days. 35 Section 13.09 Conflict with Trust Indenture Act Act. 35 Section 13.10 Counterparts Counterparts. 35 Section 13.11 Separability Separability. 35 Section 13.12 Compliance Certificates Certificates. 35 Section 13.13 U.S.A Patriot Act 35 Act. 37 Section 13.14 Force Majeure 35 Majeure. 37 Section 13.12 13.15 Table of Contents; Headings 35 ivHeadings. INDENTURE Indenture, dated as of , 20 , among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and [Trustee], as trustee (the “Trustee”):37

SUPPLEMENTAL INDENTURES 29. Section 9.01 Supplemental Indentures Without the Consent of Securityholders 29 Section 9.02 Supplemental Indentures With Consent of Securityholders 30 Section 9.03 Effect of Supplemental Indentures 30 Section 9.04 Securities Affected by Supplemental Indentures 30 Section 9.05 Execution of Supplemental Indentures 30 TABLE OF CONTENTS PAGE ARTICLE 10 SUCCESSOR ENTITY 31 Section 10.01 Company May Consolidate, Etc. 31 Section 10.02 Successor Entity Substituted 31 ARTICLE 11 SATISFACTION AND DISCHARGE 31 32 Section 11.01 Satisfaction and Discharge of Indenture 31 32 Section 11.02 Discharge of Obligations 32 Section 11.03 Deposited Moneys to be Held in Trust 32 Section 11.04 Payment of Moneys Held by Paying Agents 32 Section 11.05 Repayment to Company 32 33 ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS 33 Section 12.01 No Recourse 33 ARTICLE 13 MISCELLANEOUS PROVISIONS 33 Section 13.01 Effect on Successors and Assigns 33 Section 13.02 Actions by Successor 33 Section 13.03 Surrender of Company Powers 33 iii. Table Of Contents (continued) Page 34 Section 13.04 Notices 33 34 Section 13.05 Governing Law; Jury Trial Waiver 34 Section 13.06 Treatment of Securities as Debt 34 Section 13.07 Certificates and Opinions as to Conditions Precedent 34 Section 13.08 Payments on Business Days 34 35 Section 13.09 Conflict with Trust Indenture Act 35 Section 13.10 Counterparts 35 Section 13.11 Separability 35 Section 13.12 Compliance Certificates 35 Section 13.13 U.S.A. Patriot Act 35 Section 13.14 Force Majeure 35 Section 13.12 13.15 Table of Contents; Headings 35 iv. 36 iii INDENTURE IndentureINDENTURE, dated as of [●], 20 20__, among Synthetic Biologics, Inc.Geron Corporation, a Nevada Delaware corporation (the “Company”), and [TrusteeTRUSTEE], as trustee (the “Trustee”):